Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash from Operations: 2020-2025

Historic Cash from Operations for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to -$31.0 million.

  • Tango Therapeutics' Cash from Operations rose 7.30% to -$31.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$145.8 million, marking a year-over-year decrease of 19.21%. This contributed to the annual value of -$131.5 million for FY2024, which is 11.46% down from last year.
  • Tango Therapeutics' Cash from Operations amounted to -$31.0 million in Q3 2025, which was up 15.24% from -$36.5 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year Cash from Operations high stood at -$7.5 million for Q2 2021, and its period low was -$41.7 million during Q1 2025.
  • In the last 3 years, Tango Therapeutics' Cash from Operations had a median value of -$33.4 million in 2024 and averaged -$32.6 million.
  • Per our database at Business Quant, Tango Therapeutics' Cash from Operations tumbled by 23,493,650.00% in 2021 and then grew by 22.40% in 2023.
  • Tango Therapeutics' Cash from Operations (Quarterly) stood at -$16.9 million in 2021, then crashed by 67.23% to -$28.3 million in 2022, then rose by 2.83% to -$27.5 million in 2023, then tumbled by 33.42% to -$36.6 million in 2024, then climbed by 7.30% to -$31.0 million in 2025.
  • Its Cash from Operations stands at -$31.0 million for Q3 2025, versus -$36.5 million for Q2 2025 and -$41.7 million for Q1 2025.